Total trials
72
Active
31
Phase 3
20
Total enrollment
123,915
Pipeline matrix
Showing 40 of 70 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pumitamig | — | — | — | — | 9 | ||
| Carboplatin | — | — | — | 7 | |||
| Paclitaxel | — | — | — | 5 | |||
| Docetaxel | — | — | — | 4 | |||
| Gemcitabine | — | — | — | — | 4 | ||
| Pembrolizumab | — | — | — | — | 3 | ||
| Etoposide | — | — | — | — | 3 | ||
| Eribulin | — | — | — | — | 2 | ||
| BNT324 | — | — | — | — | 2 | ||
| BNT162b2 | — | — | — | 15 | |||
| Atezolizumab | — | — | — | — | 2 | ||
| Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose | — | — | — | — | 2 | ||
| Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose | — | — | — | — | 2 | ||
| Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose | — | — | — | — | 2 | ||
| Nab-paclitaxel/Paclitaxel | — | — | — | — | — | 1 | |
| BNT113 | — | — | — | — | — | 1 | |
| BNT162b2 Vaccine | — | — | — | — | — | 1 | |
| BNT323/DB-1303 | — | — | — | — | — | 1 | |
| Doxorubicin | — | — | — | — | — | 1 | |
| Pemetrexed | — | — | — | — | — | 1 | |
| Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose | — | — | — | — | — | 1 | |
| Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose | — | — | — | — | — | 1 | |
| Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose | — | — | — | — | — | 1 | |
| Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose | — | — | — | — | — | 1 | |
| Prednisone/prednisolone | — | — | — | — | — | 1 | |
| BNT327 | — | — | — | — | — | 3 | |
| BNT326 | — | — | — | — | — | 2 | |
| BNT314 | — | — | — | — | 2 | ||
| BNT327 Dose Level 1 | — | — | — | — | — | 2 | |
| Bevacizumab | — | — | — | — | — | 2 | |
| BNT164a1 | — | — | — | — | 2 | ||
| BNT164b1 | — | — | — | — | 2 | ||
| mFOLFIRINOX | — | — | — | — | — | 2 | |
| Nab-paclitaxel | — | — | — | — | — | 2 | |
| BNT166a | — | — | — | — | — | 2 | |
| RO7198457 intravenous | — | — | — | — | — | 1 | |
| Itraconazole | — | — | — | — | — | 1 | |
| Paroxetine | — | — | — | — | — | 1 | |
| BNT329 | — | — | — | — | — | 1 | |
| CA19-9-targeting monoclonal antibody | — | — | — | — | — | 1 |
30 more active programs hidden
Next readouts
- 2026-03-12
- 2026-07-23
- 2026-07-31
- 2026-07-31
- 2026-10
- 2026-11
- 2026-11
- 2027-06
- 2027-06
- 2027-06
Top conditions
- COVID-1920
- SARS-CoV-2 Infection12
- Solid Tumor5
- Advanced Solid Tumor3
- Non-small Cell Lung Cancer3
- SARS-COV-2 Infection3
- Tuberculosis2
- SARS-CoV-22
Frequently asked questions about BioNTech SE
- How many clinical trials does BioNTech SE have on ClinicalTrials.gov?
- BioNTech SE is listed as the lead sponsor on 72 clinical trials in ClinicalTrials.gov, 31 of which are currently active (recruiting, enrolling, or ongoing).
- How many of BioNTech SE's trials are in Phase 3?
- 20 of BioNTech SE's trials are in Phase 3, spread across 70 active drug programs.
- What therapeutic areas does BioNTech SE focus on?
- BioNTech SE's most-studied conditions on ClinicalTrials.gov are COVID-19, SARS-CoV-2 Infection, Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer.
- When are BioNTech SE's next clinical trial readouts?
- BioNTech SE has 10 upcoming primary-completion readouts tracked here; the soonest is “Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers”, expected around 2026-03-12.